Related Experiment Video
Updated: Oct 11, 2025
Pooled shRNA Screen for Reactivation of MeCP2 on the Inactive X Chromosome
Published on: March 2, 2018
Chromatin state profiling reveals PRC2 inhibition as a therapeutic target in NRAS-mutant melanoma
1Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract:
Recently, we have generated 284 epigenomic maps in melanoma. Using chromatin state profiling we identify an association of NRAS-mutants with bivalent Histone H3 lysine 27 trimethylation (H3K27me3) and broad H3K4me3 domains. Reprogramming of bivalent H3K27me3 occurs on critical invasive-regulators and its resolution using Enhancer of Zeste Homolog 2 (EZH2) inhibition reduces invasive capacity and tumor burden in NRAS-mutant patient samples.
Insights
Researchers mapped melanoma epigenomes, finding NRAS-mutant tumors associate with specific histone modifications. Inhibiting EZH2 reduced tumor invasion and burden in NRAS-mutant melanoma patients.
Area of Science:
- Cancer Biology
- Epigenetics
- Melanoma Research
Background:
- Melanoma epigenomics is complex, with NRAS mutations influencing tumor behavior.
- Histone modifications like H3K27me3 and H3K4me3 play roles in gene regulation.
Purpose of the Study:
- To investigate the epigenomic landscape of melanoma, particularly in NRAS-mutant subtypes.
- To explore the therapeutic potential of targeting epigenetic regulators in melanoma.
Main Methods:
- Generation and analysis of 284 epigenomic maps in melanoma.
- Chromatin state profiling to identify associations between NRAS mutations and histone modifications.
- Assessment of Enhancer of Zeste Homolog 2 (EZH2) inhibition in preclinical models.
Main Results:
- NRAS-mutant melanoma is associated with bivalent Histone H3 lysine 27 trimethylation (H3K27me3) and broad H3K4me3 domains.
- Reprogramming of bivalent H3K27me3 was observed on genes regulating invasion.
- EZH2 inhibition led to reduced invasive capacity and tumor burden in NRAS-mutant samples.
Conclusions:
- Epigenetic reprogramming, specifically involving H3K27me3, is linked to melanoma invasiveness in NRAS-mutant tumors.
- Targeting EZH2 represents a promising therapeutic strategy for NRAS-mutant melanoma.
